GlassScriptPhysician profile
Raymond W Acus
NPI 1518079003
$4,983.31
in general payments reported to CMS, 2019-2025
15 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,612 · 2020: $194 · 2021: $115 · 2022: $180 · 2023: $211 · 2024: $470 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rock Medical Orthopedics, INC. | $2,375.58 | 2019-2020 | |
| Arthrex, INC. | $1,165.63 | 2019 | |
| Smith+Nephew, INC. | $871.02 | 2020-2025 | Legion, Journey II, Real Intelligence |
| Vericel Corporation | $132.86 | 2020-2024 | Maci |
| Paragon 28, INC. | $89.44 | 2024 | Ankle Fracture |
| Stryker Corporation | $79.82 | 2021-2025 | Augment Injectable, Tornier Perform Reversed Glenoid, Blueprint Patient Specific Instrumentation |
| Depuy Synthes Sales INC. | $65.71 | 2021 | |
| Djo, LLC | $60.33 | 2019 | |
| Horizon Therapeutics Plc | $36.91 | 2019-2022 | |
| Innovation Technologies INC | $23.44 | 2021 | |
| Forte Bio-Pharma LLC | $21.91 | 2024 | Prolate, Nalocet |
| Bioventus LLC | $21.82 | 2024 | Durolane |
| Vertex Pharmaceuticals Incorporated | $19.15 | 2025 | |
| Pfizer INC. | $11.18 | 2020 | |
| Fidia Pharma USA INC. | $8.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Acus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.